QUANTUM GENOMICS Inactive Instrument
QUANTUM GENOMICS Share Price Euronext Paris
Equities
FR0011648971
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - EUR | - |
|
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.5M 4.82M 402M |
|---|---|---|---|---|---|
| Net income 2024 * | -3M -3.21M -268M | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | 8.7M 9.31M 776M | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.44
x | P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.23% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | - | |
Lionel Ségard
FOU | Founder | 56 | 23/05/23 |
Benoît Gueugnon
DFI | Director of Finance/CFO | - | 01/18/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lionel Ségard
FOU | Founder | 56 | 23/05/23 |
François Pelen
BRD | Director/Board Member | 66 | - |
| Chief Executive Officer | 63 | - |
Quantum Genomics is a biotechnology company that specializes in the research and development of drugs for the treatment of cardiovascular diseases such as high blood pressure and heart failure.
All sales are abroad.
| 1st Jan change | Capi. | |
|---|---|---|
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
